FDA Guidance Policy Could Be Hurt By Ruling On Animal Drug Compounding

A recent court ruling on the compounding of animal drugs has grabbed the attention of pharma lawyers, who say it could have ramifications for other FDA policies and provide ammunition for those challenging the agency’s use of guidance documents.